-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, the 2021 full-year transcripts of listed pharmaceutical companies have basically been announced
.
From the perspective of industry segments, the in vitro diagnostic industry has performed outstandingly, with an overall good news rate of over 80%.
Among them, the growth rate of many companies such as Rejing Bio, Jiu'an Medical, Yirui Bio, Jiuqiang Bio, and Oriental Bio has doubled
.
Recently, another in-vitro diagnostic company, Rui Ang Gene, released its annual report, which is also the company's first "transcript" after its listing on the Science and Technology Innovation Board.
Highlights in the report are frequent
.
The annual report released by Reon Gene on the evening of April 19 shows that in 2021, the company will achieve operating income of 291 million yuan, a year-on-year increase of 2.
11%; net profit attributable to the parent is 47.
3326 million yuan, a year-on-year increase of 22.
26%
.
Basic earnings per share were 0.
95 yuan
.
The company stated in its annual report that during the reporting period, the company's operating income was the same as the same period of the previous year, but the revenue structure was significantly improved, and the core products and services grew rapidly
.
From the perspective of specific product revenue, the blood disease molecular diagnostic kit products have made most of the contributions to the company, bringing a total revenue of 174 million yuan, a year-on-year increase of 23.
46%; while the conventional clinical laboratory self-built project only received revenue of 32.
4137 million yuan, However, it increased by 221.
67% year-on-year
.
The 2021 annual report shows that the company's leukemia product revenue accounts for half of the total revenue
.
Rayon Gene's existing leukemia product line includes 3 fusion gene kits, WT1 kits, NGS testing services,
etc.
Among them, 3 kinds of fusion gene kit products obtained the third-class medical device certificate in 2012, and have no domestic competitors for up to 6 years, making the company occupy more than two-thirds of the leukemia fusion gene detection market.
.
It is worth noting that in the first quarter of 2022, the company also obtained medical device registration certificates for 15 fusion gene detection kit products
.
The company stated in its annual report, "The number of gene site detections for 15 fusion gene products has increased by 5 times, and the unit price is expected to increase by about 2-3 times; the coverage rate of leukemia patients with fusion genes has increased from 50% to more than 95%.
, resulting in approximately 1x the number of patients being tracked
.
"It is reported that these products will become domestic exclusive products in the next few years, which will help further consolidate the company's dominant position in the domestic leukemia molecular detection field
.
Reion Gene mentioned in previous institutional surveys that the three fusion genes of leukemia, covering 50% of the population can be used for initial and follow-up.
The company currently occupies more than 70% of the initial detection market share of fusion genetic screening
.
According to reports, there are about 75,000 new cases in the domestic leukemia field every year.
Due to the long survival period, The number of patients in stock is huge
.
According to the admission price of the company's existing products and services, the domestic leukemia molecular detection business capacity is estimated to be about 3.
5 billion yuan
.
The 15-gene product has increased the business capacity of the existing first-time patients by about 250 million to 2.
55 billion , the existing capacity of tracking patients has increased by about 200 million to 2.
5 billion, and the total market capacity is 3.
95 billion
.
According to public information, Rayon Gene was listed on the Shanghai Stock Exchange on May 17, 2021, and the company's main business is in vitro diagnostic products ( Including the research and development, production, sales and scientific research and testing services of testing instruments and testing reagents), mainly for blood diseases (leukemia, lymphoma), solid tumors (lung cancer, colorectal cancer, melanoma, etc.
) and infectious diseases (hepatitis B) , rubella, herpes simplex, etc.
) patients with accurate detection of genes and antigens, provide the basis for the formulation of individualized treatment plans such as disease diagnosis, risk assessment, disease classification, targeted drug selection and efficacy monitoring
.
Disclaimer: In any case The information or opinions expressed in this article do not constitute investment advice to anyone
.
.
From the perspective of industry segments, the in vitro diagnostic industry has performed outstandingly, with an overall good news rate of over 80%.
Among them, the growth rate of many companies such as Rejing Bio, Jiu'an Medical, Yirui Bio, Jiuqiang Bio, and Oriental Bio has doubled
.
Recently, another in-vitro diagnostic company, Rui Ang Gene, released its annual report, which is also the company's first "transcript" after its listing on the Science and Technology Innovation Board.
Highlights in the report are frequent
.
The annual report released by Reon Gene on the evening of April 19 shows that in 2021, the company will achieve operating income of 291 million yuan, a year-on-year increase of 2.
11%; net profit attributable to the parent is 47.
3326 million yuan, a year-on-year increase of 22.
26%
.
Basic earnings per share were 0.
95 yuan
.
The company stated in its annual report that during the reporting period, the company's operating income was the same as the same period of the previous year, but the revenue structure was significantly improved, and the core products and services grew rapidly
.
From the perspective of specific product revenue, the blood disease molecular diagnostic kit products have made most of the contributions to the company, bringing a total revenue of 174 million yuan, a year-on-year increase of 23.
46%; while the conventional clinical laboratory self-built project only received revenue of 32.
4137 million yuan, However, it increased by 221.
67% year-on-year
.
The 2021 annual report shows that the company's leukemia product revenue accounts for half of the total revenue
.
Rayon Gene's existing leukemia product line includes 3 fusion gene kits, WT1 kits, NGS testing services,
etc.
Among them, 3 kinds of fusion gene kit products obtained the third-class medical device certificate in 2012, and have no domestic competitors for up to 6 years, making the company occupy more than two-thirds of the leukemia fusion gene detection market.
.
It is worth noting that in the first quarter of 2022, the company also obtained medical device registration certificates for 15 fusion gene detection kit products
.
The company stated in its annual report, "The number of gene site detections for 15 fusion gene products has increased by 5 times, and the unit price is expected to increase by about 2-3 times; the coverage rate of leukemia patients with fusion genes has increased from 50% to more than 95%.
, resulting in approximately 1x the number of patients being tracked
.
"It is reported that these products will become domestic exclusive products in the next few years, which will help further consolidate the company's dominant position in the domestic leukemia molecular detection field
.
Reion Gene mentioned in previous institutional surveys that the three fusion genes of leukemia, covering 50% of the population can be used for initial and follow-up.
The company currently occupies more than 70% of the initial detection market share of fusion genetic screening
.
According to reports, there are about 75,000 new cases in the domestic leukemia field every year.
Due to the long survival period, The number of patients in stock is huge
.
According to the admission price of the company's existing products and services, the domestic leukemia molecular detection business capacity is estimated to be about 3.
5 billion yuan
.
The 15-gene product has increased the business capacity of the existing first-time patients by about 250 million to 2.
55 billion , the existing capacity of tracking patients has increased by about 200 million to 2.
5 billion, and the total market capacity is 3.
95 billion
.
According to public information, Rayon Gene was listed on the Shanghai Stock Exchange on May 17, 2021, and the company's main business is in vitro diagnostic products ( Including the research and development, production, sales and scientific research and testing services of testing instruments and testing reagents), mainly for blood diseases (leukemia, lymphoma), solid tumors (lung cancer, colorectal cancer, melanoma, etc.
) and infectious diseases (hepatitis B) , rubella, herpes simplex, etc.
) patients with accurate detection of genes and antigens, provide the basis for the formulation of individualized treatment plans such as disease diagnosis, risk assessment, disease classification, targeted drug selection and efficacy monitoring
.
Disclaimer: In any case The information or opinions expressed in this article do not constitute investment advice to anyone
.
